- Current Issue
- Accepted Manuscripts
vqn佛跳墙旧版
Special Issue Photo Quiz蚂蚁vp加速器官网
Special Issue Photo QuizAnswer to August 2023 Photo Quiz
vqn佛跳墙旧版
Special Issue Editorialvpn 购买:2021-6-5 · vpn 购买 佛跳墙cpn 加速器应用 快区加速器下载地址 威皮恩下载 UU加速器 上外网 天行nvp下载 v2ray padavan 64m WWW.BJN26.COM 绿灯安卓破解版 中信加速器 装上这个番强利器加速气就 布谷666 伋理上网加速 bacloud 飞鱼星vp750 免费ss账号分享 ...
veee加速器电脑 EditorialSpecial Issue on Diagnostic Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Lessons from This Pandemic
vqn佛跳墙旧版
Special Issue The Brief CaseThe Brief Case: “Not Positive” or “Not Sure”—COVID-19-Negative Results in a Symptomatic Patient
veee加速器电脑 The Brief CaseClosing the Brief Case: “Not Positive” or “Not Sure”—COVID-19-Negative Results in a Symptomatic Patient
vqn佛跳墙旧版
Special Issue MinireviewComparative Pathogenesis of Bovine and Porcine Respiratory Coronaviruses in the Animal Host Species and SARS-CoV-2 in HumansDiscovery of bats with severe acute respiratory syndrome (SARS)-related coronaviruses (CoVs) raised the specter of potential future outbreaks of zoonotic SARS-CoV-like disease in humans, which largely went unheeded. Nevertheless, the novel SARS-CoV-2 of bat ancestral origin emerged to infect humans in Wuhan, China, in late 2023 and then became a global pandemic. Less than 5 months after its emergence, millions of people worldwide have...
vqn佛跳墙旧版
Special Issue BacteriologyBacteremia and Blood Culture Utilization during COVID-19 Surge in New York CityA surge of patients with coronavirus disease 2023 (COVID-19) presenting to New York City hospitals in March 2023 led to a sharp increase in blood culture utilization, which overwhelmed the capacity of automated blood culture instruments. We sought to evaluate the utilization and diagnostic yield of blood cultures during the COVID-19 pandemic to determine prevalence and common etiologies of bacteremia and to inform a diagnostic approach...
vqn佛跳墙旧版
Special Issue VirologyEvaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 DetectionIn the race to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), efficient detection and triage of infected patients must rely on rapid and reliable testing. In this work, we performed the first evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel (QIAstat-SARS) for SARS-CoV-2 detection. This assay is the first rapid multiplex PCR (mPCR) assay, including SARS-CoV-2 detection, and is fully compatible with a non-...
旋风vp加速器 Virology爱开红包app下载|爱开红包下载 v2.0.1 安卓版_最火软件站:2021-11-22 · 最火软件站提供爱开红包下载,爱开红包 是一款伍红包为主题的趣玩聊天交友平台，每日定时红包雨，随时随地捡红包,快分享给好朋友一起捡红包！ 软件特点 1.有钱途的聊天交友，土豪一言不合就发 …The global coronavirus (CoV) disease 2023 (COVID-19) pandemic has resulted in a worldwide shortage of viral transport media and raised questions about specimen stability. The objective of this study was to determine the stability of severe acute respiratory syndrome CoV 2 (SARS-CoV-2) RNA in specimen transport media under various storage conditions. Transport media tested included UTM, UTM-RT, ESwab, M4, and saline (0.9% NaCl). Specimen...
Special Issue VirologyComparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal SpecimensSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2023 (COVID-19), was first discovered in December 2023 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly nonspecific, and symptoms overlap those of other seasonal respiratory infections concurrently circulating in the population....
Special Issue VirologyClinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-...
Special Issue VirologyComparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories免费: quickq 官网下载 下载-windows: quickq 官网下载:2021-6-9 · 免费: quickq 官网下载 下载软件在 UpdateStar: quickq 官网下载 的搜索结果
Special Issue Virologyladder加速器-客户端下载:2021-3-24 · ladder加速器下载,ladder加速器app好用吗？ladder加速器安卓版和ladder加速器苹果版有什么特色？独享ISP骨干网国际专线出墙，畅刷油管奈飞，雷霆旋风般的速度稳定看4K高品质稳定线路跨境加速器。安全私密畅游全球网络The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a severe international shortage of the nasopharyngeal swabs that are required for collection of optimal specimens, creating a critical bottleneck blocking clinical laboratories’ ability to perform high-sensitivity virological testing for SARS-CoV-2. To address this crisis, we designed and executed an innovative, cooperative, rapid-response...
Special Issue Virology免费: quickq 官网下载 下载-windows: quickq 官网下载:2021-6-9 · 免费: quickq 官网下载 下载软件在 UpdateStar: quickq 官网下载 的搜索结果Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as the cause of a worldwide pandemic. Many commercial SARS-CoV-2 reverse transcription-PCR (RT-PCR) assays have received Emergency Use Authorization from the U.S. Food and Drug Administration. However, there are limited data describing their performance, in particular the performance of high-throughput SARS-CoV-2 RT-PCR systems. We analyzed the diagnostic...
Special Issue VirologyLarge-Scale, In-House Production of Viral Transport Media To Support SARS-CoV-2 PCR Testing in a Multihospital Health Care Network during the COVID-19 PandemicThe COVID-19 pandemic has severely disrupted worldwide supplies of viral transport media (VTM) due to widespread demand for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-PCR (RT-PCR) testing. In response to this ongoing shortage, we began production of VTM in-house in support of diagnostic testing in our hospital network. As our diagnostic laboratory was not equipped for reagent production, we took...
Special Issue VirologyMulticenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 TestNucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow rapid therapeutic interventions. We evaluated the analytical and clinical performance characteristics of the Xpert Xpress SARS-CoV-2 (Xpert) test, a rapid,...
Special Issue VirologyClinical Performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 Detection in Nasopharyngeal Specimens from COVID-19 Patients in Hong KongIn December 2023, the coronavirus disease 2023 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in the Hubei province of China and later spread all over the world. There was an urgent need of a high-throughput molecular test for screening the COVID-19 patients in the community. The Luminex NxTAG CoV extended panel is a high-throughput FDA emergency use-authorized molecular...
Special Issue VirologyComparison of Two Commercial Molecular Tests and a Laboratory-Developed Modification of the CDC 2023-nCoV Reverse Transcriptase PCR Assay for the Detection of SARS-CoV-2We compared the ability of 2 commercial molecular amplification assays (RealTime SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbott] and ID Now COVID-19 [abbreviated IDNOW; Abbott]) and a laboratory-developed test (modified CDC 2023-nCoV reverse transcriptase PCR [RT-PCR] assay with RNA extraction by eMag [bioMérieux] and amplification on QuantStudio 6 or ABI 7500 real-time PCR system [abbreviated CDC COV]) to detect severe...
Special Issue VirologyInfluence of Different Inactivation Methods on Severe Acute Respiratory Syndrome Coronavirus 2 RNA Copy NumberThe outbreak of coronavirus disease 2023 (COVID-19) has spread across the world and was characterized as a pandemic. To protect medical laboratory personnel from infection, most laboratories inactivate the virus causing COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in clinical samples before testing. However, the effect of inactivation on the detection results remains unknown. Here, we used a digital PCR assay...
Special Issue VirologyClinical Performance of SARS-CoV-2 Molecular TestsMolecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2023 (COVID-19), but the clinical performance of these tests is still poorly understood, particularly with regard to disease course, patient-specific factors, and viral shedding. From 10 March to 1 May 2023, NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338...
Special Issue VirologyCulture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19Real-time reverse transcription-PCR (RT-PCR) is currently the most sensitive method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2023 (COVID-19). However, the correlation between detectable viral RNA and culturable virus in clinical specimens remains unclear. Here, we performed virus culture for 60 specimens that were confirmed to be positive for SARS-CoV-2 RNA by real-time RT-...
Special Issue VirologyComparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal SpecimensSeveral point-of-care (POC) molecular tests have received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The test performance characteristics of the Accula (Mesa Biotech) SARS-CoV-2 POC test need to be evaluated to inform its optimal use. The aim of this study was to assess the test performance of the Accula SARS-CoV-2 test...
Special Issue VirologyPerformance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic InstitutionThe recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has posed formidable challenges for clinical laboratories seeking reliable laboratory diagnostic confirmation. The swift advance of the crisis in the United States has led to Emergency Use Authorization (EUA) facilitating the availability of molecular diagnostic assays without the more rigorous examination to which tests are normally...
Immunoassays
Special Issue ImmunoassaysPerformance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, IdahoCoronavirus disease 2023 (COVID-19), the novel respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with severe morbidity and mortality. The rollout of diagnostic testing in the United States was slow, leading to numerous cases that were not tested for SARS-CoV-2 in February and March 2023 and necessitating the use of serological testing to determine past infections. Here, we...
Special Issue Immunoassays迅游网游加速器iOS游戏下载_ 迅游网游加速器安卓版下载 ...:电脑版下载 手机扫码下载游戏 礼包领取 迅游网游加速器介绍 专业的网游加速器-迅游网游加速器,新用户免费试用!有效解决玩家在网络游戏中遇到的延时过高,登录困难,容易掉线等问题,迅游网游加速器为网游保驾 …While the coronavirus disease 2023 (COVID-19) pandemic has peaked in many countries already, the current challenge is to assess population immunity on a large scale. Many serological tests are available and require urgent independent validation. Here, we report performance characteristics of Orient Gene Biotech COVID-19 IgG/IgM Rapid Test Cassette (OG) and compare it to Abbott SARS-CoV-2 IgG immunoassay (ASIA). Patients (n = ...
Special Issue ImmunoassaysPerformance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2Veee最新版下载-Veee苹果版下载-Appfound:2021-4-3 · Veee最新版是一款全新的功能性加速软件，使用异常的方便，轻松使用更安全！无需ROOT权限，给你不一样的全新体验！想要手机拥有无限加速体验，感受顺畅的操作享受，感兴趣的小伙伴记得点击appfound手游网下载
Letters to the Editor
蚂蚁vp加速器官网 Letter to the EditorValidation of the Hologic Aptima Unisex and Multitest Specimen Collection Kits Used for Endocervical and Male Urethral Swab Specimens (Aptima Swabs) for Collection of Samples from SARS-CoV-2-Infected Patients
Special Issue Letter to the EditorComparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19
Special Issue Letter to the Editor免费: quickq 官网下载 下载-windows: quickq 官网下载:2021-6-9 · 免费: quickq 官网下载 下载软件在 UpdateStar: quickq 官网下载 的搜索结果
Special Issue Letter to the EditorSaliva as a Noninvasive Specimen for Detection of SARS-CoV-2
Special Issue Letter to the EditorComparison of Abbott ID Now and Abbott m2000 Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Symptomatic Patients
Special Issue Letter to the EditorEvaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs
Special Issue Letter to the EditorPatients with Common Cold Coronaviruses Tested Negative for IgG Antibody to SARS-CoV-2
Special Issue Letter to the EditorStability of SARS-CoV-2 in Phosphate-Buffered Saline for Molecular Detection
蚂蚁vp加速器官网 Letter to the Editorvpn中国:2021-4-20 · 蚂蚁加速器test 蜂鸟Ⅴpn加速器 电脑vp IP地址端口号8389 世宇什么意思 苹果手机越狱 比来加速器 WWW.S7664.COM 22rrr. com 手机更换日本网络节点 iss免费账号24小时更新 蚂蚁宝卡 猪猪伋刷平台 免费跳墙软件 ns伋理服务器设置自动验证 佛跳
Special Issue Letter to the EditorTest Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges
Special Issue Letter to the EditorPreprocedural Surveillance Testing for SARS-CoV-2 in an Asymptomatic Population in the Seattle Region Shows Low Rates of Positivity
Special Issue Letter to the EditorMulticenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens
Erratum
ErratumErratum for McTaggart et al., “Phylogeny and Identification of Nocardia Species on the Basis of Multilocus Sequence Analysis”
旋风vp加速器
Author CorrectionCorrection for Khan et al., “Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options”
Masthead
MastheadEditorial Board
NEW:COVID-19 Research and News from ASM Journals
Current Issue
Submit a Manuscript
蚂蚁vp加速器官网
Journal of Clinical Microbiology® (JCM) publishes the most current research related to the laboratory diagnosis of human and animal infections and the role of the laboratory in both the management of infectious diseases and the elucidation of the epidemiology of infections.
Editor in Chief: Dr. Alexander J. McAdam
For Authors
ios 加速器vp
Watch Diagnostic Tests for COVID-19 a discussion about laboratory testing for COVID-19 with two experts, Dr. Melissa Miller and Dr. Elitza Theel. Hosted by Journal of Clinical Microbiology Editor in Chief, Dr. Alexander McAdam.
- Most Read
- Most Cited
- Laboratory Diagnosis of COVID-19: Current Issues and Challenges
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho
- Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage
- Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2
vqn佛跳墙旧版
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. The diagnosis of acute coronavirus disease 2023 (COVID-19) is critically dependent on the detection of SARS-CoV-2 RNA from clinical specimens (e.g., nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence...
An outbreak of coronavirus disease 2023 (COVID-19) caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) began in Wuhan, Hubei, China, in December 2023 and spread rapidly worldwide. The response by the Alberta Precision Laboratories, Public Health Laboratory (ProvLab), AB, Canada, included the development and implementation of nucleic acid detection-based assays and dynamic changes in testing...
Testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) got off to a slow start in the United States. In this commentary, I describe my experience with CoV disease 2023 (COVID-19), with a focus on being tested at the University of North Carolina—Chapel Hill Respiratory Diagnostic Center on its inaugural day.
In this commentary, we provide a broad overview of how the rapidly evolving coronavirus disease 2023 (COVID-19) diagnostic landscape has impacted clinical care during the COVID-19 pandemic. We review aspects of both molecular and serologic testing and discuss the logistical challenges faced with each. We also highlight the progress that has been made in the development and implementation of these assays as well as the need for ongoing...
In early March 2023, the University of Washington Medical Center clinical virology laboratory became one of the first clinical laboratories to offer testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). When we first began test development in mid-January, neither of us believed there would be more than 2 million confirmed SARS-CoV-2 infections nationwide or that we would have performed more than 150,000 real-time PCR...